Arbutus Biopharma Corp. Cash flow Statement
Figures in Million
Consolidated Cash Flow Results
Dec'24
Dec'23
Dec'22
Dec'21
Dec'20
Dec'19
No of Months
12
12
12
12
12
12
Profit Before Tax
-69.00
-72.00
-65.00
-76.00
-61.00
-151.00
Adjustment
0.00
0.00
0.00
0.00
0.00
0.00
Changes In working Capital
-2.00
-18.00
29.00
0.00
0.00
-2.00
Cash Flow after changes in Working Capital
0.00
0.00
0.00
0.00
0.00
0.00
Cash Flow from Operating Activities
-64.00
-85.00
-35.00
-67.00
-51.00
-71.00
Cash Flow from Investing Activities
22.00
50.00
-74.00
-12.00
-14.00
28.00
Cash Flow from Financing Activities
51.00
30.00
31.00
137.00
86.00
37.00
Net Cash Inflow / Outflow
10.00
-4.00
-78.00
57.00
20.00
-5.00
Opening Cash & Cash Equivalents
0.00
0.00
0.00
0.00
0.00
0.00
Cash & Cash Equivalent on Amalgamation / Take over / Merger
0.00
0.00
0.00
0.00
0.00
0.00
Cash & Cash Equivalent of Subsidiaries under liquidations
0.00
0.00
0.00
0.00
0.00
0.00
Translation adjustment on reserves / op cash balances foreign subsidiaries
0.00
0.00
0.00
0.00
0.00
0.00
Effect of Foreign Exchange Fluctuations
0.00
0.00
0.00
0.00
0.00
0.00
Closing Cash & Cash Equivalent
0.00
0.00
0.00
0.00
0.00
0.00
Figures in USD Million
Seasonal companies are compared with the same quarter last year
Seasonal companies are compared with the same quarter last year
Compare Cash Flow Results of Arbutus Biopharma Corp.
Figures in Million
consolidated Cash Flow Results
Change(USD)
Change(%)
Profit Before Tax
-69.9200000000806
28.507
-97.00
-345.27%
Adjustment
0
0
0.00
0.00%
Changes In working Capital
-2.82900000000326
55.894
-57.00
-105.06%
Cash Flow after changes in Working Capital
0
0
0.00
0.00%
Cash Flow from Operating Activities
-64.8500000000748
-20.44
-44.00
-217.27%
Cash Flow from Investing Activities
22.9480000000265
230.321
-208.00
-90.04%
Cash Flow from Financing Activities
51.99600000006
-186.974
237.00
127.81%
Net Cash Inflow / Outflow
10.0450000000116
22.907
-12.00
-56.15%
Opening Cash & Cash Equivalents
0
0
0.00
0.00%
Cash & Cash Equivalent on Amalgamation / Take over / Merger
0
0
0.00
0.00%
Cash & Cash Equivalent of Subsidiaries under liquidations
0
0
0.00
0.00%
Translation adjustment on reserves / op cash balances foreign subsidiaries
0
0
0.00
0.00%
Effect of Foreign Exchange Fluctuations
-0.0490000000000565
0
0.00
0.00%
Closing Cash & Cash Equivalent
0
0
0.00
0.00%
Cash Flow - Snapshot (Consolidated) - Dec'24
YoY Growth in year ended Dec 2024 is 24.54% vs -143.06% in Dec 2023
Dec'24
Dec'23
Change(%)
Cash Flow from Operating Activities
-64.85
-85.94
24.54%






